VNRX.AMEXVolitionrx LTD
10-Q: VolitionRx Reports Q3 2025 Loss, Boosts Capital Amid Going Concern
Sentiment:
Quarterly Report
VolitionRx Limited reported a net loss of $17.2 million for the nine months ended September 30, 2025, while actively raising capital and expanding commercialization efforts for its diagnostic tests.
Capital raiseCompany entered into a Senior Secured Convertible Promissory Note with Lind Global Asset Management XII LLC for $7.5 million, along with warrants to purchase 13,020,834 shares of common stock, generating approximately $5.8 million in net cash proceeds.March 2025 Registered Direct Offering: Issued 2,363,636 shares to insiders and 1,739,087 shares with warrants to other investors, raising $2.3 million net.August 2025 Registered Direct Offering: Issued 156,250 shares to insiders and 1,734,375 shares with warrants to other stockholders, raising $1.21 million net.September 2025 Private Placement: Issued 483,870 shares and warrants to an existing stockholder, raising $0.3 million net.2025 ATM Sales Agreement with JonesTrading: Raised approximately $880,862 net through the sale of 1,386,223 shares from April 22, 2025, through September 30, 2025.Amendment to 2025 ATM Sales Agreement on August 14, 2025, increased the maximum aggregate offering price from $7.5 million to $30.0 million.Subsequent to September 30, 2025, an Underwritten Public Offering closed on October 14, 2025, raising approximately $5.4 million net, with an additional $582,426 from the partial exercise of an Over-Allotment Option on November 7, 2025.The company explicitly states it expects to rely on additional future financing through licensing, grant funding, and sale of equity or debt securities.
Worse than expectedThe company continues to report significant net losses ($17.2 million for nine months ended September 30, 2025).Cash and cash equivalents have drastically reduced to $0.2 million, indicating a critical liquidity position.Negative cash flow from operating activities persists at $14.2 million.The auditors have issued a going concern opinion, highlighting substantial doubt about the company's ability to continue operations without further financing.Total liabilities significantly exceed total assets, and the company has a substantial accumulated deficit.
Summary
- Net loss for the nine months ended September 30, 2025, was $17.2 million, an improvement from $21.4 million in the prior year.
- Cash and cash equivalents stood at $0.2 million as of September 30, 2025, down from $3.3 million at December 31, 2024.
- Operating cash flow was negative $14.2 million for the nine months ended September 30, 2025.
- Total revenues increased by 23% to $1.3 million for the nine months ended September 30, 2025, driven by Nu.Q Vet Cancer Test and Nu.Q Discover kit sales, and Nu.Q Discover services.
- Research and development expenses decreased by 36% to $7.6 million for the nine months ended September 30, 2025, due to reduced clinical trial activity and personnel expenses.
- General and administrative expenses increased by 21% to $7.7 million, primarily due to higher stock-based compensation and legal/professional fees.
- Sales and marketing expenses decreased by 29% to $2.9 million.
- The company raised approximately $10.9 million in net cash from financing activities during the nine months ended September 30, 2025, including a $7.5 million convertible note and warrants, registered direct offerings, and ATM sales.
- A material weakness in internal controls over financial reporting was identified due to insufficient written documentation of policies and procedures.
- The company's ability to continue as a going concern is dependent on obtaining additional financing.
Sentiment
Score: 3
Explanation: The company continues to face significant financial challenges, including substantial net losses, negative operating cash flow, and a critical cash position, leading to a going concern warning. While revenue growth and R&D cost reduction are positive, they are insufficient to offset the overall financial distress and heavy reliance on dilutive capital raises.
Positives
- Net loss decreased to $17.2 million for the nine months ended September 30, 2025, from $21.4 million in the prior year, representing a 20% improvement.
- Total revenues increased by 23% to $1.3 million for the nine months ended September 30, 2025, compared to $1.0 million in the prior year, driven by product and service sales.
- Research and development expenses decreased by 36% to $7.6 million, reflecting completion of certain clinical trials and studies, indicating cost control.
- Successful capital raises, including a $7.5 million Senior Secured Convertible Promissory Note and warrants, and multiple registered direct offerings, provided $10.9 million in net cash from financing activities.
- Expansion of Nu.Q Vet Cancer Test availability to over twenty countries.
- New strategic agreements: Research License and Exclusive Commercial Option Rights Agreement with Werfen for Antiphospholipid Syndrome (APS) and co-marketing agreement with Hologic Diagenode for Nu.Q Discover service.
Negatives
- Continued significant net loss of $17.2 million for the nine months ended September 30, 2025.
- Negative cash flow from operating activities of $14.2 million for the nine months ended September 30, 2025.
- Cash and cash equivalents significantly decreased to $0.2 million as of September 30, 2025, from $3.3 million at December 31, 2024.
- Accumulated deficit reached $246.6 million as of September 30, 2025.
- Auditors included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- General and administrative expenses increased by 21% to $7.7 million, partly due to higher legal and professional fees and stock-based compensation.
- Identified material weakness in internal controls over financial reporting due to insufficient written documentation.
- Significant contractual payment obligations totaling $18.2 million, with $3.0 million due in the remaining part of 2025.
Risks
- Need to raise additional capital in the future.
- Possibility of not being able to continue to operate, as indicated by the going concern opinion from auditors.
- Inability to generate significant revenues or achieve profitability.
- Difficulties in managing growth due to expansion of product development and sales/marketing capabilities.
- Dependence on third-party distributors.
- Limited experience with sales and marketing.
- Ability to successfully develop, manufacture, market, and sell future products.
- Ability to timely obtain necessary regulatory clearances or approvals.
- Market acceptance of future products.
- Highly competitive and rapidly changing nature of the diagnostics market.
- Protection of patents, intellectual property, and trade secrets.
- Reliance on third parties to manufacture and supply intended products.
- Material weaknesses in internal control over financial reporting.
- Pressures related to macroeconomic and geopolitical conditions.
- Risk that effective implementation of plans will not result in necessary funding to continue operations and satisfy debt obligations.
- Risk of being forced to cease operations if unable to obtain adequate capital.
Future Outlook
The company expects to incur further losses in the future, particularly from continued development of its clinical-stage diagnostic tests and commercialization activities. Management plans to address liquidity needs by granting licenses/distribution rights, obtaining additional debt or equity financing, securing grant funds, and efficiently developing/commercializing products. The company aims to remain an IP powerhouse in the epigenetic space and monetize intellectual property through licensing and distribution contracts. Cash reserves are intended to predominantly fund further research and development, and commercialization activities.
Management Comments
- Our operations are transitioning from a research and development stage to a commercialization stage.
- We aim to partner with established diagnostic companies and/or liquid biopsy companies to market, sell, and process our tests, leveraging their networks and expertise.
- We believe, given the global prevalence of cancer and diseases associated with NETosis, and the low-cost, accessible and routine nature of our tests, they could potentially be used throughout the world.
- We aim to remain an IP powerhouse in the epigenetic space and expect to monetize our IP and technologies through licensing and distribution contracts.
- Management continues to exercise tight cost controls and has implemented short-term cash preservation and cost-saving initiatives to conserve cash.
- Management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing.
Industry Context
The company operates in the highly competitive and rapidly changing diagnostics market, specifically focusing on epigenetics, nucleosomes, and transcription factors as biomarkers for cancer and NETosis-associated diseases like sepsis. Its commercialization strategy involves partnering with established diagnostic and liquid biopsy companies, leveraging their networks for global reach, and monetizing intellectual property through licensing and distribution. The expansion of the Nu.Q Vet Cancer Test into over twenty countries and new agreements with Werfen (specialized diagnostics for hemostasis, thrombosis, NETs-related indications) and Hologic Diagenode (co-marketing Nu.Q Discover) indicate efforts to penetrate diverse segments of the diagnostics industry, from companion animal healthcare to human specialized diagnostics and research services.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Material Weakness in Internal Controls | Identified a material weakness in internal controls over financial reporting due to insufficient written documentation of policies and procedures, including correct application of GAAP and SEC disclosure requirements. | 2025-09-30 | Could adversely affect the ability to record, process, summarize, and report financial information accurately and timely. |
| Remediation Plan for Internal Controls | Planned remediation efforts include replacing outside service providers to centralize accounting, engaging internal control consultants for risk assessment and system design, preparing written documentation of policies, and engaging external consultants for complex GAAP applications. | Aims to strengthen internal control over financial reporting and remediate identified material weaknesses. | |
| Compensation Committee Approval | Approved cash bonuses of up to two months gross salary and RSU grants of 2,868,000 shares under the 2024 Plan, tied to corporate goals (licensing, revenue, cost reduction, non-dilutive funding). | 2025-03-17 | Intended to incentivize personnel towards achieving corporate goals and align interests with company performance. |
Legal Proceedings
- The company knows of no legal proceedings which it believes will have a material adverse effect on its financial position.
- The company is not involved as a plaintiff in any material proceeding or pending litigation.
- There are no proceedings in which directors, officers, affiliates, or any registered or beneficial stockholders are an adverse party or have a material interest adverse to the company's interest.
Related Party Transactions
- Common stock issued to certain directors and executive officers in the March 2025 Registered Direct Offering (2,363,636 shares).
- Common stock issued to certain directors and executive officers in the August 2025 Registered Direct Offering (156,250 shares).
- Stock options, warrants, and RSUs issued to related parties.
- Agreements with related parties for the purchase of consultancy services, accrued under management and directors fees payable.
- Certain directors and officers agreed to purchase an aggregate of 254,229 shares and accompanying warrants in the October 2025 Underwritten Offering.
Stakeholder Impact
- Shareholders face significant dilution from ongoing equity raises and potential loss of investment due to going concern uncertainty, though future value could emerge from diagnostic test commercial success.
- Employees and management receive significant stock-based compensation and cash bonuses tied to corporate goals, but job security is at risk due to going concern issues if financing is not secured.
- Creditors are exposed to risk due to the company's accumulated deficit and going concern uncertainty, with the Lind Note offering some security as a Senior Secured Convertible Promissory Note.
- Customers may benefit from the continued development and commercialization of new diagnostic tools (Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer).
- Suppliers and partners are engaged through ongoing research and collaboration agreements and new partnerships (Werfen, Hologic Diagenode), indicating continued business activity.
Next Steps
- Continue development of clinical-stage diagnostic tests.
- Continue commercialization activities for products like Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, and Nu.Q Cancer.
- Grant licenses and/or distribution rights to third parties.
- Obtain additional financing through debt or equity transactions.
- Secure additional grant funds.
- Develop and commercialize products in an efficient manner.
- Remediate material weaknesses in internal controls over financial reporting, including centralizing accounting, engaging internal control consultants, preparing written documentation, and using external consultants for complex GAAP applications.
- Potential future sales of equity securities through the 2025 ATM Sales Agreement or other financings.
- Werfen to investigate clinical utility of Nu.Q H3.1 NETs assay in APS patients and potentially negotiate an exclusive commercial license.
- Hologic Diagenode to co-market Nu.Q Discover service, with an aim for exclusive provider status if successful.
Key Dates
| Date | Description |
|---|---|
| 2015-07-23 | 292,000 vested stock options under the 2011 Equity Incentive Plan expired. |
| 2018-01-01 | Company entered into a research collaboration agreement with the University of Taiwan for a three-year research period. |
| 2019-02-11 | Expiration date for 545,000 outstanding options granted on this date was extended to February 11, 2029. |
| 2022-05-20 | Company entered into an equity distribution agreement (2022 EDA) with Jefferies LLC for an at-the-market offering. |
| 2023-07-01 | Company entered into a research agreement with Xenetic Biosciences Inc and CLS Therapeutics Ltd. |
| 2023-08-01 | Company entered into a project research agreement with Guys and St Thomas NHS Foundation Trust. |
| 2024-01-01 | Company entered into an agreement with the University Medical Centre Amsterdam (UMC) for a retrospective study. |
| 2024-03-12 | Company issued 129,132 shares of restricted common stock to EpiCypher, Inc. for license rights. |
| 2024-08-08 | Company entered into a securities purchase agreement for a registered direct offering (2024 Equity Capital Raise), issuing common stock, pre-funded warrants, Series A and Series B common stock warrants. |
| 2024-10-01 | Company entered into an agreement with the National Taiwan University for a clinical research study. |
| 2024-11-08 | Company's Registration Statement on Form S-3 (Reg. No. 333-283088) filed with the SEC. |
| 2024-12-05 | Company entered into a securities purchase agreement for a registered direct offering, issuing common stock and December 2024 Warrants. |
| 2025-01-01 | ASU 2023-05, Business CombinationsJoint Venture Formations, adopted by the Company. |
| 2025-01-01 | 21,583 RSUs vested under the 2015 Plan. |
| 2025-01-15 | 16,912 RSUs granted under the 2015 Plan with a 12-month vesting period; 50,000 RSUs granted under the 2015 Plan with a 36-month vesting period. |
| 2025-01-29 | Company amended terms of certain outstanding options granted pursuant to the 2015 Plan, extending expiration date for 545,000 shares to February 11, 2029. |
| 2025-02-05 | Company entered into a 9-month loan agreement with First Insurance Funding for up to $294,603. |
| 2025-02-11 | 40,000 vested stock options previously granted to a consultant were cancelled. |
| 2025-02-22 | 4,667 RSUs vested under the 2015 Plan. |
| 2025-02-26 | 125,000 RSUs granted under the 2015 Plan with a 67-day vesting period; 25,000 RSUs granted under the 2024 Plan with a 77-day vesting period. |
| 2025-03-01 | 154,678 RSUs granted under the 2024 Plan with a 12-month vesting period. |
| 2025-03-07 | 12,500 RSUs granted under the 2015 Plan with a 12-month vesting period. |
| 2025-03-13 | 33,503, 38,198, and 41,642 RSUs vested under the 2015 Plan. |
| 2025-03-17 | Compensation Committee approved cash bonuses and RSU grants (2,868,000 shares) under the 2024 Plan. |
| 2025-03-20 | 26,200 vested stock options previously granted to an employee were cancelled. |
| 2025-03-24 | Company entered into a securities purchase agreement for a registered direct offering, issuing common stock and March 2025 Warrants. |
| 2025-04-04 | 31,667 RSUs vested under the 2015 Plan. |
| 2025-04-15 | Registration Statement on Form S-1 (File No. 333-286401) declared effective by SEC. |
| 2025-04-18 | Company's registration statement on Form S-3 (Reg. No. 333-283088) declared effective by the SEC. |
| 2025-04-20 | 2022 Equity Distribution Agreement with Jefferies LLC terminated. |
| 2025-04-22 | Company entered into a Capital On DemandTM Sales Agreement (2025 ATM Sales Agreement) with JonesTrading Institutional Services, LLC. |
| 2025-05-01 | A holder of Pre-Funded Warrants partially exercised warrants, purchasing 1,958,273 shares of common stock. |
| 2025-05-05 | 200,000 RSUs granted under the 2024 Plan with an 8-day vesting period. |
| 2025-05-13 | 125,000 RSUs vested under the 2015 Plan; 225,000 RSUs vested under the 2024 Plan. |
| 2025-05-15 | Company entered into a securities purchase agreement with Lind Global Asset Management XII LLC, issuing a Senior Secured Convertible Promissory Note ($7.5 million) and a Common Stock Purchase Warrant. |
| 2025-05-23 | 37,334 RSUs vested under the 2015 Plan. |
| 2025-05-28 | 171,291 vested stock options previously granted to an employee were cancelled. |
| 2025-06-01 | 343,192 RSUs vested under the 2015 Plan; 137,452 RSUs granted under the 2015 Plan with a 2-month vesting period. |
| 2025-06-15 | 8,667 RSUs vested under the 2015 Plan; 51,722 vested stock options previously granted to an employee were cancelled. |
| 2025-06-23 | 50,000 RSUs vested under the 2015 Plan; 50,000 RSUs granted under the 2015 Plan with 0-day vesting; 50,000 RSUs granted under the 2015 Plan with 21-day vesting; 50,000 RSUs granted under the 2015 Plan with 52-day vesting. |
| 2025-06-30 | 95,618, 95,599, and 95,583 RSUs cancelled under the 2024 Plan. |
| 2025-07-01 | 138,452 RSUs vested under the 2015 Plan. |
| 2025-07-07 | A holder of Pre-Funded Warrants partially exercised warrants, purchasing 991,000 shares of common stock. |
| 2025-07-13 | 4,667 and 50,000 RSUs vested under the 2015 Plan. |
| 2025-07-14 | Resale Registration Statement on Form S-3 (File No. 333-288508) declared effective by the SEC. |
| 2025-07-24 | 300,000 RSUs granted under the 2024 Plan with variable vesting up to 42 months. |
| 2025-08-01 | 137,452 RSUs vested under the 2015 Plan. |
| 2025-08-04 | Company entered into a securities purchase agreement for a registered direct offering, issuing common stock and August 2025 Warrants. |
| 2025-08-13 | 50,000 RSUs vested under the 2015 Plan. |
| 2025-08-14 | Company entered into Amendment No. 1 to the 2025 ATM Sales Agreement, increasing maximum offering price to $30.0 million. |
| 2025-08-15 | 101,700 RSUs granted under the 2015 Plan with 78-day vesting; 101,694 RSUs granted under the 2015 Plan with 171-day vesting; 5,000 RSUs granted under the 2015 Plan with 47-day vesting; 5,000 RSUs granted under the 2015 Plan with 139-day vesting. |
| 2025-09-11 | 2,000 RSUs vested under the 2015 Plan. |
| 2025-09-13 | 7,875, 7,875, 9,000, 4,228 RSUs cancelled under the 2015 Plan. |
| 2025-09-18 | Company entered into a securities purchase agreement for a private placement, issuing 483,870 shares of common stock and September 2025 Warrants. |
| 2025-09-23 | A holder of Pre-Funded Warrants partially exercised warrants, purchasing 608,000 shares of common stock. |
| 2025-09-28 | 282,825 RSUs vested under the 2015 Plan. |
| 2025-09-30 | 5,000 RSUs vested under the 2015 Plan; 4,200, 4,200, and 4,200 RSUs cancelled under the 2024 Plan. |
| 2025-10-04 | 282,659 RSUs vested, resulting in issuance of 216,966 shares and 65,693 shares withheld for taxes. |
| 2025-10-06 | 5,000 RSUs previously granted to a consultant vested and resulted in the issuance of 5,000 shares of common stock. |
| 2025-10-10 | Company entered into an Underwriting Agreement with Newbridge Securities Corporation for an underwritten public offering. |
| 2025-10-14 | Underwritten public offering closed, generating approximately $5.4 million in net proceeds. |
| 2025-11-01 | 101,700 RSUs previously granted to executive officers of the Company or its subsidiaries vested and resulted in the issuance of 81,867 shares of common stock with 19,833 shares of common stock withheld for taxes. |
| 2025-11-06 | 133,334 RSUs previously granted to a director of the Company vested and resulted in the issuance of 133,334 shares of common stock. |
| 2025-11-07 | Company and Underwriter amended the Underwriting Agreement; Underwriter exercised Over-Allotment Option for 1,194,000 Option Shares and 1,732,500 Option Warrants, generating an additional $582,426 in net proceeds. |
| 2025-11-13 | Date of filing of this Quarterly Report on Form 10-Q. |
Recommendation
strong sellThe company faces severe financial distress, evidenced by a substantial accumulated deficit, persistent net losses, and critically low cash reserves. The explicit 'going concern' warning from auditors, coupled with heavy reliance on continuous, dilutive capital raises to sustain operations, indicates a high risk of further share price erosion and potential inability to continue as an operating business. While there are ongoing R&D and commercialization efforts, the fundamental financial instability makes the stock a strong sell for investors seeking capital preservation or growth.
Keywords
VolitionRx, VNRX, quarterly report, financial results, net loss, cash flow, going concern, diagnostics, epigenetics, Nu.Q Vet Cancer Test, Nu.Q NETs, Nu.Q Discover, cancer detection, sepsis, liquid biopsy, capital raise, convertible note, warrants, registered direct offering, ATM offering, internal controls, material weakness, research and development, commercialization, biomarkers, nucleosomes, Antiphospholipid Syndrome, Werfen, Hologic Diagenode, stock-based compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.